A medication name is not a complete description of a treatment program. Everest eClinic, also called Everest Diabetes & Weight Loss, advertises semaglutide, tirzepatide and other prescription options through a Connecticut telehealth practice. For someone comparing GLP-1 services, the important distinction is between what Everest documents about its own care and what outside research establishes about particular medicines. Neither a familiar ingredient nor a published clinical trial verifies the results of this clinic’s program.
The public documentation consulted October 19, 2026, describes a free introductory call, individual nurse practitioner visits, a $79 monthly membership and medication charges billed separately. It also leaves consequential questions unanswered, including which formulations match advertised prices and who dispenses shipped prescriptions. This review treats the clinic’s service descriptions and credentials as attributed statements, not independently verified findings. The organizing question is practical: what can a prospective patient reasonably establish before paying, and what still requires a written answer?
At a glance
- Practice and geography
- Everest describes a virtual-only Connecticut clinic created in 2023 for medical weight loss, diabetes care and nutrition counseling.
- Membership
- $79 per month includes practitioner visits, secure between-visit messaging, medication coverage assistance and clinically appropriate refills; medication costs are separate.Sources: [7]
- Medication price ranges
- Everest advertises semaglutide at $159–$299 per month and tirzepatide at $249–$399 per month. The price blocks do not identify formulations; brand-name costs vary by insurance.Sources: [8]
- Clinical process
- The clinic describes a one-hour initial provider evaluation and follow-ups typically every six weeks to three months, depending on the treatment plan and progress.Sources: [7]
Start with the practice, not the ingredient
Everest’s privacy policy identifies Oaktree Health and Wellness, LLC as the business operating under Everest Diabetes & Endocrinology, Everest Diabetes & Weight Loss and Everest Eclinic. Those names are expressly connected in the documentation; they should not automatically be treated as separate providers. The clinic says it was created in 2023 to offer integrated medical weight loss, diabetes care and nutrition counseling to people in Connecticut. The consulted pages do not establish weight-loss program availability beyond that state.
The site names Geeta Sharma, DNP, NP-C as founder. It reports a Doctor of Nursing Practice degree from Quinnipiac University in 2019 and a post-master’s certification in diabetes, endocrinology and metabolism from Duke University in 2020. These are the practice’s credential statements, not independent license or certification checks. Its FAQ describes individual care with a board-certified nurse practitioner at every visit; that professional designation should not be rewritten as physician care.
Everest publishes a Branford address, but explicitly says it offers no in-person visits. Telemedicine is available Monday through Saturday, with published hours of 9 a.m.–6 p.m. weekdays and 9 a.m.–noon Saturdays. Those hours establish an advertised schedule, not a guaranteed appointment or message-response time. Our guide to what public provider documents can prove explains why an identifiable business and a described service are useful evidence without being proof of clinical performance.
What happens between the introductory call and treatment
The first step is advertised as a free, no-obligation, 15-minute telephone consultation, requested by calling or texting 203-689-0558. Staff confirm the appointment during regular business hours. Everest says this call reviews medical history, health goals and needs to determine whether the program is a fit. It is distinct from the longer clinical evaluation, so prospective patients should not assume the free call includes a completed prescribing assessment or a prescription.
After enrollment, staff email instructions for accessing the patient portal and uploading required documents before the provider visit. Subsequent nurse practitioner appointments use a telehealth link sent by text and email, described by Everest as secure. The initial provider evaluation lasts one hour and covers medical and nutritional history, with medication recommendations when appropriate and guidance on nutrition, habits and exercise. The sequence is reasonably clear, although the documents do not establish the waiting time between these steps.
Everest says treatment selection is individualized around medical history and coexisting conditions, in collaboration with the patient. That is a process description, not an assurance of eligibility for a particular medicine. Everest’s treatment page lists semaglutide contraindications including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), and hypersensitivity to semaglutide. These stated restrictions are not a complete set of program admission criteria. The consulted pages do not establish a complete minimum-age policy, BMI requirements or all admission criteria. A useful pre-enrollment request is therefore specific: ask what records and assessments are required, when the paid membership begins, and what happens financially if the clinical evaluation does not lead to medication.
The medication list is broader than a single GLP-1 offer
Everest lists Ozempic, Mounjaro, Trulicity, Victoza and Saxenda alongside education and individual weight-management counseling. Its treatment page also lists oral options including phentermine, metformin and Topamax. This documents a broader prescribing model than a one-product subscription. It does not establish immediate availability of every listed brand, or show that every medicine carries an approved weight-loss indication. The oral-medication section describes insurance coverage as often broader with little out-of-pocket expense, but supplies no guaranteed patient price.
The membership language expressly includes access to name-brand or compounded medications. Yet the semaglutide and tirzepatide price blocks do not identify the formulation, route, presentation or dispensing pharmacy associated with their ranges. A product mentioned elsewhere on the site cannot safely fill those gaps. Before comparing offers, ask for the exact prescribed product, whether it is approved or compounded, how it is administered, and which pharmacy will dispense it at the quoted price.
FDA approval belongs to a specific product, not to Everest as a clinic. FDA also states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. These are separate questions, explored in our guide to approved medicines and compounded preparations.
Clinical research does not measure Everest’s outcomes
The distinction matters because Everest’s treatment page mixes references to Ozempic and Wegovy when discussing studies and results. This review does not adopt those statements as verified outcomes for the practice. Public descriptions of a drug study cannot establish how Everest’s patients fare, how many discontinue treatment, or whether a particular compounded preparation produces the same results. No independently verified provider-specific outcome data were established by the consulted documentation.
For perspective, STEP 1 studied 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks. Mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo; both groups received lifestyle intervention. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%. Novo Nordisk funded the trial. The dose identifies the research arm only, not patient instructions, and those findings do not predict an individual’s response.
That study is evidence for its studied intervention and population—not a performance report for this clinic, its compounded products, different routes or other regimens. It also cannot establish results for Everest’s diabetes-care population, because STEP 1 excluded diabetes. Our explanation of why a clinical trial is not a telehealth company performance report makes that boundary explicit. The appropriate conclusion is neither that Everest’s care works exactly like the trial nor that missing clinic-specific results prove it ineffective.
Read the prices as separate, incompletely connected offers
The clearest recurring charge is the $79 monthly membership. Everest says it includes all practitioner visits, secure messaging between visits, assistance verifying medication coverage and refills when clinically appropriate. The treatment page adds laboratory ordering and preparation of a receipt or superbill for possible HSA/FSA reimbursement. Ordering laboratory work does not establish that the testing charge is included. The FAQ explicitly separates medication costs, although the sentence explaining how those costs vary is unfinished.
The monthly medication ranges are visible and should not be obscured by general uncertainty: semaglutide is advertised at $159–$299 and tirzepatide at $249–$399. The same blocks say brand-name medication cost varies by insurance. Limited-time starter offers are also displayed, but their relationship to the membership is unclear. Neither their duration nor the phrase “package” establishes an exact supply quantity, a minimum commitment or mandatory advance payment.
The table separates the offers rather than combining them into an unsupported total. Everest advertises the semaglutide special as $45 per week with $90 savings, and the tirzepatide special as $69 per week with $50 savings. Those are provider-stated promotional comparisons, not independently calculated savings. The consulted pages do not settle promotion expiration dates, access requirements, included shipping or supplies, or subsequent charges. Request a written itemization of the first payment and the next regular charge.
| Offer | Published charge | Important boundary |
|---|---|---|
| Membership | $79 per month | Medication separate; laboratory ordering does not establish testing is included |
| Semaglutide medication | $159–$299 per month | Formulation unspecified; brand-name cost varies by insurance |
| Tirzepatide medication | $249–$399 per month | Formulation unspecified; brand-name cost varies by insurance |
| Limited-time semaglutide starter package | $399 for nine weeks | Membership inclusion, supply quantity and payment timing unclear |
| Limited-time tirzepatide starter package | $549 for eight weeks | Membership inclusion, supply quantity and payment timing unclear |
Insurance assistance is not insurance acceptance
Everest says it does not accept insurance for its services. Separately, it says patients may use insurance for medications at their preferred pharmacy and for laboratory testing, depending on the plan. These statements describe different payment channels, not a contradiction. Membership assistance with checking medication coverage does not mean the consultation is covered, or that a plan will authorize a particular prescription. NIDDK likewise notes that medication coverage varies and requires confirmation with the individual plan.
The clinic says it accepts HSA and FSA payments and allows patients to submit visit claims for possible insurance reimbursement. It also offers receipt or superbill preparation. None of that guarantees reimbursement, establishes tax treatment or replaces checking the relevant plan’s rules. A prospective patient should ask whether a specific medication quote assumes insurance approval, which pharmacy channel it uses, and what the out-of-pocket alternative would be if coverage is denied.
Everest advertises holiday and special-event promotions, directing patients to staff for current offers. Its FAQ also promises $50 off the next follow-up appointment for referring a friend or family member. That discount needs explanation because the monthly membership says all practitioner visits are included. The documents do not clarify whether it reduces membership charges, applies to a separate appointment arrangement or follows another rule. Treat it as a question to resolve, not as a dependable reduction in total cost.
Follow-up is described; delivery responsibilities are less complete
Everest typically schedules follow-ups every six weeks to three months, depending on goals, treatment and progress. Its visit descriptions include medical evaluation, an individualized plan, nutrition education, goal setting and monitoring. That provides more substance than a refill-only description, while leaving open how someone obtains an earlier review when needed. As NIDDK explains, follow-up concerns response and tolerability, not just continued payment. The published interval is not a guaranteed schedule for every patient.
Between visits, the membership includes secure messaging, and the treatment page mentions texting the practice with questions. The privacy policy draws an important boundary: ordinary email and text messages are not fully secure, detailed clinical communication belongs in the portal, and these channels are not for emergencies. Marketing texts are optional and not a condition of booking or receiving services. Telephone, email and portal contact remain alternatives. None of these access statements establishes round-the-clock clinical availability or a response deadline.
Everest offers the option of medication delivery to the home, but the consulted pages do not identify dispensing or compounding pharmacies, shipping fees, carriers, dispatch or arrival targets, tracking, refrigeration procedures, or replacement terms for lost or damaged shipments. Those are unresolved responsibilities, not proof that safeguards are absent. For injectable deliveries, FDA explicitly advises not using a GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or pharmacy. Our delivery-claims guide explains what documentation to request.
Cancellation language leaves several financial boundaries open
The treatment page advertises membership cancellation at any time, with “No commitment or contracts.” That is useful flexibility language, but it does not answer every billing question. The consulted documentation does not specify automatic renewal mechanics, the charge date, the effective cancellation method, prorating or refunds. Cancellation should therefore not be read as a promise to return an already collected payment. Ask for the actual procedure and confirmation of when future charges stop before enrolling.
Appointment cancellation is a separate rule. Everest requires at least 48 hours’ notice to cancel or reschedule, and late cancellations or no-shows may incur a $50 fee. The membership’s no-commitment statement does not necessarily waive that charge. Patients should ask how notice must be delivered and whether canceling membership also cancels already scheduled appointments. The 48-hour deadline concerns appointments; the consulted pages do not establish it as a membership-renewal notice requirement.
These questions can be raised through the published telephone number, 203-689-0558, or info@everesteclinic.com. A useful written response would connect the advertised membership, medication selection, dispensing pharmacy, promotion and cancellation terms in one individualized quotation. It would also identify who handles clinical concerns and delivery problems. That request does not require choosing a treatment in advance; it simply turns disconnected website statements into a service description that can be evaluated before money changes hands.
Questions & answers
Is Everest’s free consultation the one-hour clinical visit?
No. Everest describes a free, no-obligation 15-minute introductory phone call and a separate one-hour initial provider evaluation. The call reviews history, goals and program fit. Ask when enrollment and billing occur between those steps; the free call does not establish that prescribing or the full clinical evaluation is free.
Does the $79 membership include semaglutide or tirzepatide?
No. The FAQ states that medication costs are separate. Membership includes practitioner visits, secure messaging, medication coverage assistance and clinically appropriate refills. Published medication ranges are $159–$299 monthly for semaglutide and $249–$399 for tirzepatide, but the price blocks do not specify formulations, and brand-name costs vary by insurance.
Do the starter packages include membership and shipping?
The consulted pages do not make that clear. Everest advertises a limited-time nine-week semaglutide package for $399 and an eight-week tirzepatide package for $549. Request confirmation of membership, visits, testing, supplies and delivery charges, plus payment timing and later pricing. Package duration alone does not establish medication quantity or a minimum commitment.
Can I use my insurance or my own pharmacy?
Everest does not accept insurance for its services, but says insurance may cover medications at a patient’s preferred pharmacy and laboratory tests, depending on the plan. It accepts HSA/FSA payments and offers documentation for possible reimbursement. Ask whether the specific proposed prescription can use that pharmacy channel; these statements do not guarantee coverage or reimbursement.
Who will see me, and can I visit the Branford office?
Everest says each visit is one-on-one with its board-certified nurse practitioner and explicitly describes the service as telemedicine only. Its published Branford address does not establish an in-person clinic option. The site identifies Geeta Sharma, DNP, NP-C as founder, but professional credentials and licenses were not independently verified for this review.
Does canceling membership eliminate appointment fees or guarantee a refund?
Neither conclusion is established. Membership is advertised as cancelable anytime without commitment, while appointments require at least 48 hours’ cancellation or rescheduling notice. Late cancellations or no-shows may incur $50. The consulted pages do not explain refunds, prorating or the effective membership cancellation procedure, so obtain those terms separately and keep confirmation of any cancellation.
Our assessment
Everest documents a recognizable Connecticut telehealth practice with a named nurse practitioner founder, a defined introductory process, a substantial initial evaluation and published membership and medication prices. Its inclusion of nutrition counseling, follow-up visits and between-visit messaging gives prospective patients concrete service features to discuss. Those are meaningful documentary strengths, not evidence of independently verified treatment results. The biggest limitations concern connecting the offer to an exact product and transaction: formulation, dispensing pharmacy, package inclusions, delivery responsibilities and renewal or refund mechanics remain unresolved. Clinical trial findings cannot close those gaps or establish Everest-specific outcomes. Before paying, the most useful next step is a written, product-specific quotation and care explanation that identifies the pharmacy, separates recurring charges from promotions, and states how follow-up and cancellation work. That would make the program easier to evaluate without assuming either that its advertised care guarantees results or that incomplete public documentation proves poor care.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Everest eClinic / Everest Diabetes & Weight Loss — about us ↗
- Everest eClinic / Everest Diabetes & Weight Loss — text messaging terms ↗
- Everest eClinic / Everest Diabetes & Weight Loss — contact us ↗
- Everest eClinic / Everest Diabetes & Weight Loss — faq ↗
- Everest eClinic / Everest Diabetes & Weight Loss — weight loss treatment ↗
- Everest eClinic / Everest Diabetes & Weight Loss — privacy policy ↗